159 related articles for article (PubMed ID: 38012675)
1. A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer.
Chen H; Zhong Q; Liu Y; Li J; Deng W; Wang J; Zhou S; Yu Z; Huang X; Huang Y; Zhen B; Wei J; Zhang W; Ruan X; Xiao L
Radiat Oncol; 2023 Nov; 18(1):193. PubMed ID: 38012675
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.
Mahantshetty U; Krishnatry R; Chaudhari S; Kanaujia A; Engineer R; Chopra S; Shrivastava S
Int J Gynecol Cancer; 2012 Oct; 22(8):1427-34. PubMed ID: 22932264
[TBL] [Abstract][Full Text] [Related]
4. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study.
Erpolat OP; Alco G; Caglar HB; Igdem S; Saran A; Dagoglu N; Aslay I; Ozsaran Z; Demirci S; Keven E; Guney Y; Akmansu M; Kilic D; Bayman E; Etiz D; Mandel NM
Eur J Gynaecol Oncol; 2014; 35(1):62-6. PubMed ID: 24654465
[TBL] [Abstract][Full Text] [Related]
5. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.
Klopp AH; Moughan J; Portelance L; Miller BE; Salehpour MR; Hildebrandt E; Nuanjing J; D'Souza D; Souhami L; Small W; Gaur R; Jhingran A
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):83-90. PubMed ID: 23582248
[TBL] [Abstract][Full Text] [Related]
6. Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin.
Lewis S; Chopra S; Naga P; Pant S; Dandpani E; Bharadwaj N; Mahantshetty U; Engineer R; Swamidas J; Ghosh J; Gupta S; Shrivastava S
Br J Radiol; 2018 Dec; 91(1092):20180005. PubMed ID: 30179056
[TBL] [Abstract][Full Text] [Related]
7. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.
Hui B; Zhang Y; Shi F; Wang J; Wang T; Wang J; Yuan W; Li Y; Liu Z
Int J Gynecol Cancer; 2014 Nov; 24(9):1648-52. PubMed ID: 25275663
[TBL] [Abstract][Full Text] [Related]
8. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
Huang J; Gu F; Ji T; Zhao J; Li G
Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the radiation dose of pelvic-bone marrow and lymphocytic toxicity in concurrent chemoradiotherapy for cervical cancer.
Zhang BZ; Li Y; Xu LM; Chai YL; Qu C; Cao YJ; Wang J; Hou HL; Zhang J
Radiat Oncol; 2023 Jan; 18(1):12. PubMed ID: 36658595
[TBL] [Abstract][Full Text] [Related]
10. Effects of bone marrow sparing radiotherapy on acute hematologic toxicity for patients with locoregionally advanced cervical cancer: a prospective phase II randomized controlled study.
Li W; Ma L; Li F; Li K; Zhang Y; Ren H; Bao X; Guo Y; Guo Y; Wang M; Li D; Duan Y; Ma X; Wang Z; Wang Y; Yin R
Radiat Oncol; 2024 Apr; 19(1):46. PubMed ID: 38594678
[TBL] [Abstract][Full Text] [Related]
11. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?
Wan J; Liu K; Li K; Li G; Zhang Z
Radiat Oncol; 2015 Aug; 10():162. PubMed ID: 26238572
[TBL] [Abstract][Full Text] [Related]
12. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
Julie DA; Oh JH; Apte AP; Deasy JO; Tom A; Wu AJ; Goodman KA
Acta Oncol; 2016; 55(2):208-16. PubMed ID: 25984929
[TBL] [Abstract][Full Text] [Related]
13. Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
Lee AY; Golden DW; Bazan JG; Kopec M; Pelizzari CA; Aggarwal S; Chang DT; Liauw SL
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):306-312. PubMed ID: 28068238
[TBL] [Abstract][Full Text] [Related]
14. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
[TBL] [Abstract][Full Text] [Related]
15. The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy.
Chen M; Wang D; Bao Z; Yi Z; Mei Z; Sun S; Xiang Q; Yang C; Yang H; Qiu H; Xie C
Radiat Oncol; 2023 Apr; 18(1):66. PubMed ID: 37031167
[TBL] [Abstract][Full Text] [Related]
16. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
[TBL] [Abstract][Full Text] [Related]
17. Single-photon emission computed tomography-defined active bone marrow-sparing volumetric-modulated arc therapy reduces the incidence of acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy: A single-center prospective randomized controlled trial.
Wang S; Liu J; Lei K; Jia Y; Wang C; Zhang X; Li T
Cancer; 2023 Jul; 129(13):1995-2003. PubMed ID: 37043337
[TBL] [Abstract][Full Text] [Related]
18. Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
Rose BS; Aydogan B; Liang Y; Yeginer M; Hasselle MD; Dandekar V; Bafana R; Yashar CM; Mundt AJ; Roeske JC; Mell LK
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):800-7. PubMed ID: 20400238
[TBL] [Abstract][Full Text] [Related]
19. Acute toxicity of postoperative intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for cervical cancer: The role of concomitant chemotherapy.
Marjanovic D; Plesinac Karapandzic V; Stojanovic Rundic S; Tomasevic A; Saric M; Miskovic I; Nidzovic B; Petrasinovic P
J BUON; 2019; 24(6):2347-2354. PubMed ID: 31983105
[TBL] [Abstract][Full Text] [Related]
20. A prospective dosimetric and clinical comparison of acute hematological toxicities in three-dimensional conformal radiation therapy and intensity modulated radiation therapy with concurrent chemotherapy in carcinoma cervix.
Avinash HU; Arul Ponni TR; Janaki MG; Kirthi Koushik AS; Kumar SM
J Cancer Res Ther; 2015; 11(1):83-7. PubMed ID: 25879342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
